MedGenome Inc. is a genomics-based diagnostics and research company delivering the best of health care by decoding genetic information contained in an individual’s genome. We are the first mover and market leader in genomics-based diagnostics and research from India with global offices in California.
Our mission is to improve global health by developing deep insights into diseases at the genetic and molecular level. Our research solutions apply cutting-edge genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large South Asian population to understand the genetic basis of cancer, metabolic disorders, eye disorders and other rare diseases. We also address important research questions in hereditary diseases, cardiovascular complications and neurological disorders.
Founder and Chairman and Global CEO
Mr. Sam Santhosh is an entrepreneur with over 25 years of experience in initiating and running successful businesses. Sam is an investor and mentor for many companies and is currently a board member at Impelsys Inc, New York, ePay Healthcare, San Francisco, SciGenom Labs, Cochin and the Centre for Commercialization of Antibodies (CCAB) Toronto, Canada.
Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992-2012. He founded Calsoft in 1992 and under Sam’s vision Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft public and listed the company in the Indian Stock Exchanges. From 2004 to 2009, Sam focused on inorganic growth through eight acquisitions including companies in U.S, UK, Japan and India. Post 2009, Sam oversaw the sale of the Calsoft group companies to different buyers across the world.
Mahesh Pratapneni specializes in incubating product companies in the education, healthcare, and data/analytics sectors. He is focused on helping launch, re-engineer and support small and mid-sized technology driven businesses. He is known for building outstanding global teams and creating value by leveraging his experience in product visualization, development and management; and his expertise in building global delivery models. Currently, Mahesh serves as Managing Director of Singapore-based Emerge Ventures. He also serves as Executive Director of MedGenome, advisor to Oversite Data Services, and Board Member of Impelsys. His previous experiences include serving as EVP of CalSoft Group; SVP of One West Bank and IndyMac Bank; and CTO of Ocwen, Financial Services. Mahesh earned his undergraduate degree in electronics and communications from IIT Madras, and his MBA from IIM Calcutta.
Mr. Dhiraj C. Rajaram is the founder of Mu Sigma Inc. and serves as its Chairman of the Board and Chief Executive Officer. At Mu Sigma, Mr. Rajaram is responsible for vision and strategic direction, building teams, aligning organizational resources to a customer centric vision and delivering profitable growth Since 2004. Mr. Rajaram has built Mu Sigma from the ground up during which time, he executed activities that included raising seed and growth capital for the venture, securing key fortune 100 customers, incubating a delivery unit and hiring key leadership members into Mu Sigma.Before Mu Sigma, Mr. Rajaram advised senior executives across a variety of verticals as a strategy consultant at Booz Allen Hamilton and PriceWaterhouseCoopers. Mr. Rajaram holds an MBA from the University of Chicago. He has also received an M.S. in Computer Engineering from Wayne State University and a Bachelor’s degree in Electrical Engineering from College of Engineering Guindy, Anna University.
Abhay is a Managing Director with Sequoia Capital. Based in Mumbai, Abhay spearheads investments in the healthcare, energy and outsourcing sectors. Some of his investments include Moolchand Hospitals, GVK Biosciences, Coastal Projects and Ind-Bharath Power. Prior to joining Sequoia Capital, Abhay was head of Real Estate and Infrastructure investment banking at DSP Merrill Lynch where he led capital raising for the largest Indian companies in these sectors including the largest Indian initial public offering for DLF Ltd. Previously, Abhay worked at McKinsey & Co, in Mumbai and Johannesburg, where he worked with a number of leading Indian corporations in the Media & Entertainment and Manufacturing sectors. Abhay received an MBA from IIM Calcutta and a B. Tech. in Computer Science and Engineering from IIT Bombay.
Dr. Stephan C Schuster is currently the Research Director and Professor at the Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technical University, Singapore. Dr .Schuster has over 15 years of experience setting up and operating centralized sequencing core labs at Max Plank Institute in Germany and Penn State in the US. He won the Science magazine’s break through of the year award in 2006 (runner up) and 2008 (Top 10).He, was also awarded the Time Magazine’s top ten Scientific discoveries in 2008 and along with W. Miller was among Time magazine’s top 100 most influential people of 2009.
Dr. I. C. Verma is currently the head of the Department of Genetic Medicine at Sri Ganga Ram Hospital, New Delhi. Previously was a Professor of Pediatrics and Genetics in AIIMS, New Delhi. He received genetics training in the UK, USA & Switzerland. He is a Fellow of the Royal College of Physicians, London, the American Academy of Pediatrics, and the National Academy of Medical Sciences, New Delhi. He has received a number of national awards – Ranbaxy Science Award, ICMR, NAMS and BC Roy Medical Council award. He is a Member and Vice-chairman of the Ethics Committee of the International Human Genome Organization (HUGO) and serves as a genetics adviser for the WHO in Geneva, and to Roche Genetics in Basel. He has recently been mentioned in The Limca Book of Records 2003 as a pioneer in genetics in India. He has vast experience in genetic counseling, serving about 2000 cases with genetic problems every year, and bringing the benefits of genetics and genomics to large number of patients.
Dr. Satish Menon is the founder and CEO of UV Labs, a company focused on building innovative products and technologies to help solve the increasingly complex issues facing higher education today, in sectors such as healthcare and information technology.
Throughout his career, Satish has led the development of multiple technological innovations in education and digital media, including the development of data-driven personalized learning management platforms, several mobile products, and a suite of education-to-career tools for post-secondary learners..
Prior to founding UV Labs, Satish was the Chief Technology Officer for Apollo Group, a Fortune 500 company and one of the world’s largest private education providers. In that role and in his term as CIO for the company, Satish was responsible for the design and development of all consumer-facing technology, as well creating cloud-enabled education-as-a-service solutions for the company. Prior to his work at Apollo Group, Satish held roles as Chief Architect of Yahoo Media, Engineering General Manager for Video Platforms and Vice-President in the Consumer Platforms team at Yahoo.
Satish earned his Ph.D. in computer science from the Georgia Institute of Technology, as well as an M.S. in computer science and an M.S. in mechanical engineering from the New Jersey Institute of Technology. Deeply passionate about higher education and the role technology can play in transforming it, Satish holds several patents (issued and pending) in the areas of personalized learning delivery, content management and video technologies.
Dr. C.N. Ramchand is the CEO of Saksin Lifesciences and has a strong expertise in drug discovery and research, and has had a highly successful career across India, EU and the US. Prior to joining Saksin, Dr Ramchand was the CEO of Laila Pharmaceuticals and a Director at KEMIN Pharma India (a subsidiary of Kemin Pharma Belgium BVBA) and was simultaneously holding a position as Director of Research and Development, Kemin Industries South Asia Pvt. Ltd (a part of Kemin Industries Inc., Demoines, USA). In addition, Dr Ramchand was also a global executive team member of Kemin Industries.
Dr. Ramchand holds a PhD in Biochemistry from MS University Baroda. He also served as assistant professor from 1982-84 at MS University. He has also obtained his M Phil from the same University. He holds a Masters degree in Chemistry from the University of Kerala. He is also the 3 time winner of the Young Scientist award from Charing Cross and Westminster Medical School, UK for the work of the role of membrane pathology in schizophrenia and the development of EPA as a therapy for schizophrenia. He has extensive experience in basic research activities having handled prestigious projects in the US and UK, both at Universities and Pharma Industries. He has over 25 years of rich experience in the areas of teaching, basic research, drug discovery programs , study of disease mechanisms, guiding M Sc. / Ph D. students and setting up a Research facility.
Prior to the assignment at Kemin Industries, Dr Ramchand served as Vice President and Head of Drug Discovery Research (1999-2004) at Sun Pharmaceuticals Industries- the largest Pharma company in India (currently No 1 in-terms of market capitalization). He was closely involved in setting up a multi million dollar Drug Discovery center including design and development of laboratories. He had developed 3 molecules while at Sun Pharma which are currently in Phase II trials. He has also held the position of Joint Coordinator and Head of the Laboratory research program in Biomedical sciences, University of Sheffield and Northern General Hospital Sheffield, UK (1994-1999)- a prestigious University Position. Prior to this, he was the Sr. Scientist and Project Head at Institute of Biological Psychiatry at University of Wales, Bangor UK (1990-1994). He has also worked as Senior Research Officer at the Biochemistry Department, University of North Wales, Bangor, UK (1987-1990). Prior to this he was also a postdoctoral fellow at University of South Carolina, USA (1984-1987).
Dr. Ramchand has published over 70 peer-reviewed papers in international journals, edited 5 books ( he’s currently writing two books on drug discovery with Tata McGraw Hill) and has applied for over 10 patents. He has made over 100 research presentations at international conferences world wide and is also currently a Sr. Visiting fellow at the University of Sheffield and University of New Castle Upon-Tyne, UK, and at the Slovakian Academy of Sciences, Slovak Republic. He has a very close research association with State University of New York at Buffalo, USA and Florida International University (Miami, USA) and also is an adjunct faculty and PhD advisor at the MS University of Baroda. Currently, Dr Ramchand is an Honorary Visiting Professor to European Nanotechnology consortium at University of Newcastle at UK.
Mr. Peterson has over 45 years of work experience in the financial services sector in USA. Based out of the San Francisco Bay area (California), he is currently the founder and President of ePay Healthcare. Prior to that, he was the President and CEO of CASHNet for over 25 years. He also founded and partnered at PBL Associates. Mr. Peterson completed his education from the University of California at Berkeley.
MedGenome Institutional Ethics Committee (MG-IEC) is an independent body constituted under the authority of the chairman with the primary goal of safeguarding the rights and wellbeing of research participants. The chairperson of MG-IEC is appointed from a different institution and the appointment of IEC members is solely based on their competence, experience and integrity.
The MG-IEC will review all types of research proposals involving human participants with a view to safeguard the dignity, rights, safety and wellbeing of all actual and potential research participants before approving the research proposals. The goals of research, however important, should never be permitted to override the health and wellbeing of the research subjects.
The MG-IEC will ascertain whether all the cardinal principles of research ethics viz., Autonomy, Beneficence, Non-maleficence, Respect for Free and Informed Consent, Respect for Human Dignity, Respect for Vulnerable Persons, Respect for Privacy and Confidentiality and Justice are taken care of in planning, conducting and reporting of the proposed research. For this purpose, it will look into the aspects of protocol review, selection of participants, voluntary participation of potential participants, informed consent process, risk benefit ratio, distribution of burden and benefit, maintenance of privacy and confidentiality and provisions for appropriate compensations. It will review the proposals before the commencement of the study as well as review periodically until the completion of the study through appropriate well-documented procedures.
|MEMBERS OF MG-IEC|
|Chairperson||Dr. Vijayalakshmi M|
|Member Secretary||Padmavathy R|
|Scientist||Dr. Lakshmi Mahadevan|
|Basic Medical Scientist||Dr. Kumaramanickavel G|
|Scientist||Dr Ramchand CN|
|Legal Expert/Lawyer||Srijith PR|
|Philosopher||Dr. Rajamohan EK|
|Basic Medical Scientist||Dr. Álex Baby Paul|
|Lay Person||Babu AG|
|Social Scientist / Social Worker||Vinita Vijayakumar|
Phone Number : 9496665432 / 9940678632
Founder and Chairman
Sam Santhosh founded MedGenome in 2013 as a spin off from SciGenom, which he had founded in 2009. He is a science savvy entrepreneur with close to three decades of experience in launching and running successful businesses. Passionate about science & technology, Sam firmly believes that as technology was the key driver for growth in the latter half of the 20th century, so would be genomics in the 21st century. Through MedGenome, he has transformed the medical genomics and diagnostics space in India and showed path for others to emulate. At MedGenome, he provides strategic direction, oversees business development plans and helps raise capital for future growth. He is also an investor and mentor for many other companies. Currently, he is an Advisor/Board member at Impelsys Inc, New York, ePay Healthcare, San Francisco, SciGenom Labs, Cochin, AgriGenome, Hyderabad, Emerge Ventures, Singapore and the Centre for Commercialization of Antibodies (CCAB) Toronto, Canada. Previously, he was the Founder, CEO and Managing Director of California Software Limited (Calsoft). Sam holds a degree in Engineering from University of Calicut and an MBA from IIM Calcutta. He has attended Executive education programs at MIT and Singularity University.
Director, Corporate Planning, Marketing & Communications
Hiranjith is a strategy and consulting professional with a consistent track record of delivering sustained business value through actionable business insights and recommendations. His work experience spans across multinationals such as Novartis, ZS Associates, Accenture Management Consulting and Infosys. He has partnered with global brand teams on strategic planning across multiple specialty therapeutic areas such as Transplant, Auto-immune, Anti-inflammatory and Virology and across geographies. He has also been consultant to pharmaceutical majors such as Centocor Ortho Biotech, GE, Eli Lilly & Medimmune and Telecom / Finance majors on multiple projects, driving their strategic direction. Hiranjith holds a Master’s in Business Administration and a Bachelor’s degree in Electronics & Communication.
VP, Research & Development
Dr. Chaudhuri has over 15 years experience in oncology target discovery and validation at Genentech Inc, Inpharmatica Inc, and CuraGen Corporation. He holds a Ph.D. in Biochemistry from the Indian Institute of Science, Bangalore and did his Post Doctoral research at Massachusetts General Hospital, Harvard Medical School and at the Department of Molecular & Cellular Biology, Harvard University. His graduate and post-graduate research was to understand the molecular and biochemical basis of cell surface receptor signaling, cellular metabolism and establishment and maintenance of cellular polarity. He has co-authored several papers in Science and Nature.
Chief Commercial Officer, USA
Michael’s over 25 years of executive leadership experience has been focused on successfully growing several prominent life science companies. His expertise extends through general management, marketing, business development and sales in complex international businesses. He comes with a depth of understanding in Genomics, DNA Sequencing, Drug Discovery, Cell Biology, Immunology, Proteomics and Microbiome Analysis and has has strong relationships within pharmaceutical, biotech, industrial and academic markets.
Timothy J. Triche, MD, PhD, trained as an anatomic pathologist at Wash U. Medical Center, then spent 15 years at the National Cancer Institute as a staff pathologist and researcher studying cancer biology, with an emphasis on pediatric cancer. He subsequently moved to USC/CHLA as Chair, Dep’t of Pathology and Laboratory Medicine, where he established a grant funded research program in cancer genomics. More recently he founded the Center for Personalized Medicine at CHLA and has developed a series of next-gen based cancer diagnostics and prognostics. His current research is focused on the role of long non-coding RNA in cancer progression and development of a targeted nanoparticle therapeutic platform useful in delivering a wide range of therapeutics, including small molecule agents, nucleic acid, and gene editing constructs, among others. He also serves as Laboratory Director for MedGenome NGS lab in Foster City, California.
International Business Development Consultant
Dr. Ramprasad holds a Master’s Degree and PhD from BITS, PILANI. After his post doctoral training he worked for 6 years as Scientist (Molecular Genetics) at Vision Research Foundation, Sankara Nethralaya, Chennai, India and then went on to work for 4 years at Spinco Biotech, India handling Affymetrix and Illumina technologies. He also worked as Principal Scientist at SciGenom Labs,Cochin, for a year. He has 17 peer reviewed publications to his credit.
Dr Rohit Gupta is Chief Information Officer (CIO) at MedGenome and comes with a broad expertise in the areas of computational biology, genomics, data science and bioinformatics. He has more than 14 years of experience developing and applying data-driven methods in diverse application areas such as civil infrastructure, earth sciences, e-commerce, medicine, computational biology and clinical genomics.
Dr Gupta currently also holds the position of adjunct professor at IIT-Madras and at IIIT-Delhi, where he actively participates in teaching and research activities to bridge the gap between academia and industry. As part of his appointment at IIT-Madras, he is also associated with Initiative for Biological Systems Engineering (IBSE) and Interdisciplinary Laboratory for Data Sciences (ILDS).
Among his significant previous positions, he has served as Director of Bioinformatics at Strand Life Sciences, India. He was Associate Scientist for more than a year at Genentech, USA and research collaborator for more than 6 years at Mayo Clinic, Rochester USA where he won several prestigious awards for his work.
Dr Gupta holds a B.Tech degree from IIT Roorkee and M.S & Ph.D (CS) degrees from the University of Minnesota, USA. He has several peer reviewed publications to his credit in reputed journals and international conferences.
Surajit is an avid finance professional with over 15 years of experience in well diversified sectors like E-Commerce, Retail, Media & Advertising, and Manufacturing. Prior to MedGenome, he worked with Redbus.in. His core strengths being process implementation, he is adept at building an organisation’s eco system from scratch. He has handled multiple crucial projects successfully like ERP implementation and internal control system design. He has also won many accolades, and was featured as one amongst India’s 100 Stars of Tomorrow (100 future CFOs) in 2013 in CFO-India magazine – a 9.9 Media publication. Surajit is a Chartered Accountant from ICAI.
Sanjay has been a part of Indian and multinational corporate scenario for many years, and has deftly handled roles of increased responsibility. He is a hybrid professional and comes from a background of pharmaceuticals, OTC, diagnostic & healthcare. His experience spans sales & marketing, as well as operations and includes excellence in a P&L management role as business unit head. He has won several awards, of which he regards the “Jewel in the crown” and “Regional Appreciate” awards at Ranbaxy as the most precious to him. He has a strong interest in scaling up innovative business models requiring an entrepreneurial approach to business building. Sanjay is an alumni of BIM Tech and IIFT Delhi.
VP, Research & Development (India)
Dr. Arati Khanna Gupta has over twenty years of research experience in the general area of molecular medicine. Prior to joining MedGenome, Arati was an Assistant Professor of Medicine at the Harvard Medical School and a Research Scientist at the Brigham and Women’s Hospital in Boston, USA. She has been an Affiliated Member of the Harvard Stem Cell Institute (HSCI) and an Associate member of the Dana Farber Cancer Institute, Boston.
Primarily interested in the general area of molecular hematology, she has made significant contributions to understanding the transcriptional regulation of normal and leukemia-associated myeloid differentiation, neutrophil biology and the molecular mechanism underlying bone marrow failure syndromes. Arati has over thirty publications to her credit in well regarded scientific publications, including several first and last author papers, editorials, and chapters in Hematology text books. She is currently on the editorial board of an online Hematology journal. She holds a Ph.D. in Molecular Biology (Lehigh University, PA, USA) as well as a Masters degree in Biochemistry (Maharaja Sayajirao University, Baroda, India), and has several years of post-doctoral research experience (at Yale University School of Medicine, New Haven, CT, USA).